STERIS plc Announces $2.1B Acquisition of Xodus Medical with $2.0B Bridge Facility

Acquisition Summary: STERIS to Acquire Xodus Medical

On October 11, 2026, STERIS Corporation, a wholly owned subsidiary of STERIS plc (NYSE: STE), entered into a definitive Purchase and Sale Agreement to acquire Xodus Medical, Inc. and certain related affiliates for $2.1 billion in cash at closing, subject to customary adjustments.

Key Transaction Terms

• Upfront Consideration: $2.1 billion cash at closing.
• Contingent Consideration: Up to an additional $150 million earnout payable based on the achievement of defined operating performance targets during calendar year 2028.
• Target Business: Xodus Medical is a specialty surgical products business based in Pennsylvania.
• Anticipated Closing: Expected by December 31, 2026, subject to customary closing conditions and regulatory clearances.
• Termination Rights: Either party may terminate if the acquisition does not close on or before July 12, 2027 (extendable to January 11, 2028 under certain circumstances).

Financing Details

• STERIS entered into a bridge commitment letter dated October 11, 2026, with JPMorgan Chase Bank, N.A. and Goldman Sachs Bank USA.
• The commitment parties agreed to provide up to $2.0 billion aggregate principal amount under a senior unsecured bridge facility.
• The bridge facility commitments are subject to dollar-for-dollar reduction from net cash proceeds of permanent debt financings or asset sales.

Market Impact & Strategic Considerations

This transaction represents a major expansion of STERIS's specialty surgical portfolio. Investors should monitor subsequent permanent debt issuances to take out the $2.0 billion bridge commitment, leverage metrics, and regulatory review timelines.